Despite the different cell-specific roles of the JAK-STAT pathway in IBD, JAK inhibitors were successfully introduced for the treatment of IBD patients (Figure 3).17,18 Currently, tofacitinib, filgotinib, and upadacitinib are approved for the treatment of UC and upadacitinib for CD in Europe. This evidence concerns the gene SOAT1 and inflammatory bowel disease.